Profile data is unavailable for this security.
About the company
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.
- Revenue in CNY (TTM)10.32bn
- Net income in CNY1.38bn
- Incorporated1997
- Employees12.27k
- LocationChina Resources Double-Crane Pharmaceutical Co LtdNo.1 Lize East Er RoadWangjing, Chaoyang DistrictBEIJING 100102ChinaCHN
- Phone+86 1 064398099
- Fax+86 1 064398086
- Websitehttps://www.dcpc.com/
More ▼
Mergers & acquisitions
| Acquired company | 600062:SHH since announced | Transaction value |
|---|---|---|
| China Resources Zizhu Pharmaceutical Co Ltd | 5.54% | 433.04m |
| Guizhou Tianan Pharmaceutical Co Ltd | 19.33% | 35.61m |
Data delayed at least 15 minutes, as of Apr 18 2024 08:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Taiji Industry Group Co Ltd | 15.40bn | 834.00m | 20.94bn | 12.59k | 25.11 | 5.41 | -- | 1.36 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 4.00bn | 1.02bn | 21.82bn | 1.40k | 21.27 | 3.19 | -- | 5.45 | 0.6346 | 0.6346 | 2.48 | 4.23 | 0.3813 | 0.3692 | 4.83 | 2,867,937.00 | 9.72 | 12.93 | 14.49 | 18.96 | 49.00 | 53.87 | 25.50 | 27.46 | 1.02 | -- | 0.324 | 20.30 | 0.706 | 27.25 | 2.98 | 28.26 | 42.10 | 23.27 |
| Sinocelltech Group Ltd | 2.17bn | -168.81m | 22.41bn | 2.33k | -- | -- | -- | 10.32 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Tasly Pharmaceutical Group Co Ltd | 8.64bn | 1.10bn | 23.66bn | 9.22k | 21.57 | 1.87 | -- | 2.74 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Joincare Pharmaceutical Group Ind. Co. | 16.43bn | 1.42bn | 23.71bn | 14.37k | 16.55 | 1.67 | -- | 1.44 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.32bn | 1.38bn | 23.79bn | 12.27k | 17.05 | 2.04 | -- | 2.31 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Xiamen Amoytop Biotech Co Ltd | 2.23bn | 600.08m | 23.90bn | 1.96k | 39.83 | 11.92 | -- | 10.74 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 26.11bn | 8.22k | 27.56 | 3.06 | -- | 2.98 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 26.20bn | 2.57k | -- | 4.42 | -- | 16.09 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
Data as of Apr 18 2024. Currency figures normalised to China Resources Double-Crane Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
5.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 15.50m | 1.51% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 15.38m | 1.50% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Sep 2023 | 5.79m | 0.57% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 4.23m | 0.41% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 2.96m | 0.29% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.68m | 0.26% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 1.82m | 0.18% |
| Founder Fubon Fund Management Co., Ltd.as of 30 Jun 2023 | 1.78m | 0.17% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.18m | 0.12% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2023 | 1.07m | 0.10% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
